iShares U.S. Healthcare ETF (IYH)

The iShares U.S. Healthcare ETF (IYH) is a passively managed fund that holds a diversified basket of U.S.-listed healthcare companies. It encompasses pharmaceutical manufacturers that develop and sell drugs, biotechnology firms pursuing drug discovery and development, medical-device makers, healthcare providers and insurance companies, and diagnostic and research-tools firms—capturing the full breadth of how healthcare services, products, and dollars move through the American economy.

Pharmaceutical and biotech companies

The pharmaceutical segment—typically the largest piece of IYH—includes both mega-cap pharmaceutical conglomerates and smaller, more specialized biotech firms. The mega-cap pharmas like Pfizer, Merck, Johnson & Johnson, Eli Lilly, and AbbVie are research-based companies that discover, develop, and manufacture small-molecule and biologic drugs, which they then sell globally through their own sales forces and distribution partnerships.

These are research-and-development-driven businesses with high upfront costs: a single drug candidate might cost hundreds of millions to develop and may never make it to market. Yet successful drugs can earn billions in annual revenue. The business model depends on a continuous pipeline—the company must keep moving new drugs from development into launch to replace revenue from older drugs that lose patent protection and face generic competition. This is why pharma stocks trade partly on hope: investors are betting on the company’s ability to replenish its portfolio over decades.

Biotech firms tend to be more focused, often pursuing one or a few drug targets or therapeutic areas. Some are well-established diversified biotech companies like Amgen or Gilead; others are earlier-stage, pre-revenue or low-revenue firms betting everything on a handful of clinical trials. IYH’s cap-weighted structure means the largest and most profitable biotech firms (the successes) dominate the holdings; you do not get meaningful exposure to the speculative early-stage cohort.

Medical devices and diagnostics

Medical-device makers design and manufacture the tools, instruments, and implants used in surgery, patient monitoring, and disease management. Companies like Medtronic, Boston Scientific, Zimmer Biomet, and Thermo Fisher make everything from pacemakers and orthopedic implants to laboratory instruments and diagnostics. These businesses are typically less volatile than pharma because device revenue is more stable—demand for hip replacements, dialysis machines, and laboratory tests does not swing as dramatically with drug-pipeline outcomes.

Device companies face constant competitive pressure to innovate and to contain costs—reimbursement rates from government and insurance plans are always under pressure—but they benefit from aging demographics, which drives sustained demand for joint replacements, cardiac devices, and chronic-disease management tools.

Healthcare providers and services

Hospital systems, health insurance companies, and outpatient-care providers make up a smaller but important portion of IYH. Companies like UnitedHealth, Anthem, and Elevance (formerly Cigna) are large health insurers whose business model is to receive premiums, manage claims, and keep the spread as profit. Hospital operators like HCA Healthcare and Tenet Healthcare own and operate acute-care facilities. Diversified healthcare services firms like CVS Health operate pharmacy, insurance, and primary-care networks.

This segment is historically less volatile than pharma but more dependent on healthcare policy, reimbursement regulation, and labor costs. A shift in how Medicare reimburses hospital care, or a change in insurance law, can move these stocks materially.

Healthcare infrastructure and research tools

Smaller holdings in IYH include companies that provide the enabling infrastructure for healthcare—clinical-laboratory services, contract research organizations (CROs) that run clinical trials, and diagnostic and research-tools firms. Companies like Quest Diagnostics, LabCorp, and Charles River Laboratories have recurring revenue from testing and research services; their fortunes depend on usage rates and the pace of drug development and healthcare testing across the economy.

Stability and defensive characteristics

Healthcare is often considered a defensive sector—it performs relatively well in recessions because demand for healthcare services does not collapse even when consumer spending slows. People still need medications, still get surgeries, still need medical devices. This is a real but incomplete picture: healthcare stocks do fall in recessions, they are just less volatile than cyclical sectors like industrials or energy. IYH reflects this stability; it typically has lower volatility than the broader S&P 500 and tends to hold up better in downturns.

Regulatory risk and long-term headwinds

The primary risk facing healthcare is regulatory change. Drug pricing has been politically contentious for years; changes to how Medicare negotiates drug prices or how private insurance reimburses can cut into pharma margins. Patent cliffs—when bestselling drugs lose patent protection and face generic competition—are predictable but painful events that pharma companies manage through constant pipeline advancement.

Beyond regulation, healthcare faces long-term challenges around rising development costs for new drugs, consolidation that reduces competition, and the pressure to demonstrate not just efficacy but cost-effectiveness in a world of constrained healthcare spending. These are not acute risks but structural headwinds that shape how the sector grows over decades.

Income and dividend characteristics

Healthcare companies, particularly the larger pharma and device makers, tend to pay dividends. IYH has historically offered meaningful yield, though it varies with the mix of company profitability. Insurance and provider companies often pay lower dividend yields, while established pharma typically pays higher yields.

How to research IYH

Start with the prospectus and holdings list to understand the fund’s exposure across pharma, biotech, devices, providers, and other segments. Monitor clinical trial results and pipeline developments at major pharma and biotech holdings—these drive stock prices more than quarterly earnings. Watch healthcare policy, particularly any changes to drug pricing, Medicare reimbursement, or insurance regulation. Track reimbursement rates and cost trends, especially for medical devices and healthcare services. For the insurance and provider segment, follow earnings calls to understand enrollment trends, medical loss ratios, and margin pressure. IYH’s broad diversification across healthcare subsectors means no single news item dominates the fund, making it suitable for investors convinced of healthcare’s long-term resilience but uncertain about individual company outcomes.